Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Trial of Secukinumab in Psoriasis
NCT01132612Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2010
- Primary completion
- Oct 2016
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of secukinumab in plaque psoriasis (3 arms), sponsored by Novartis. Primary endpoint: Number of Participants With Adverse Events, Serious Adverse Events and Deaths. Started May 2010; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT01132612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01132612.